{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T21:01:38Z","timestamp":1787950898967,"version":"build-2784847793"},"reference-count":83,"publisher":"Siapec Servizi Srl","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathologica"],"DOI":"10.32074\/1591-951x-1113","type":"journal-article","created":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T12:34:24Z","timestamp":1751978064000},"page":"178-198","source":"Crossref","is-referenced-by-count":4,"title":["Consensus document on preoperative diagnostic procedures in breast lesions"],"prefix":"10.32074","volume":"117","author":[{"given":"Stefano","family":"Marletta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Castellano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Caumo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Criscitiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Frittelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donatella","family":"Santini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Terribile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Bernardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Bortul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Calabrese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Catanuto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"Cattani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leopoldo","family":"Costarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"D\u2019Amati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Fusco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oreste","family":"Gentilini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moira","family":"Ragazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianni","family":"Saguatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Santinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Scatena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia","family":"Sciancalepore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Pietribiasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sapino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"21774","published-online":{"date-parts":[[2025,6]]},"reference":[{"key":"10.32074\/1591-951X-1113_ref1","unstructured":"Public Health England. Clinical guidance for breast cancer screening assessment (NHSBSP Publication No 49). London; 2016. Available at: https:\/\/www.gov.uk\/government\/publications\/breast-screening-clinical-guidelines-for-screening-management."},{"key":"10.32074\/1591-951X-1113_ref2","doi-asserted-by":"crossref","unstructured":"Sch\u00fcnemann HJ, Lerda D, Quinn C, et al. Breast Cancer Screening and Diagnosis: A Synopsis of the European Breast Guidelines. Ann. Intern. Med. 2020;172:46-56. https:\/\/doi.org\/10.7326\/M19-2125.","DOI":"10.7326\/M19-2125"},{"key":"10.32074\/1591-951X-1113_ref3","doi-asserted-by":"crossref","unstructured":"Tamaki K, Sasano H, Ishida T, et al. Comparison of core needle biopsy (CNB) and surgical specimens for accurate preoperative evaluation of ER, PgR and HER2 status of breast cancer patients. Cancer Sci. 2010;101:2074-2079. https:\/\/doi.org\/10.1111\/j.1349-7006.2010.01630.x.","DOI":"10.1111\/j.1349-7006.2010.01630.x"},{"key":"10.32074\/1591-951X-1113_ref4","doi-asserted-by":"crossref","unstructured":"Rageth CJ, O\u2019Flynn EAM, Pinker K, et al. Second International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions). Breast Cancer Res. Treat. 2019;174:279-296. https:\/\/doi.org\/10.1007\/s10549-018-05071-1.","DOI":"10.1007\/s10549-018-05071-1"},{"key":"10.32074\/1591-951X-1113_ref5","doi-asserted-by":"crossref","unstructured":"Sharma N, Cornford E, Cheung S, et al. The impact of vacuum-assisted excision in the management of indeterminate B3 lesions in the NHS Breast Screening Programme in England. Clin. Radiol. 2021;76:470.e23-470.e29. https:\/\/doi.org\/10.1016\/j.crad.2021.01.021.","DOI":"10.1016\/j.crad.2021.01.021"},{"key":"10.32074\/1591-951X-1113_ref6","unstructured":"Writing Group of the National Quality Assurance Coordinating Group for Breast Screening Pathology. Guidance. Breast screening: quality assurance guidelines for breast pathology services. 2020. Available at: https:\/\/www.gov.uk\/government\/publications\/breast-screening-quality-assurance-guidelines-for-breast-pathology-services\/breast-screening-quality-assurance-guidelines-for-screening-pathology-services#regional-delivery-of-breast-pathology-quality-and-quality. Accessed April 25, 2024."},{"key":"10.32074\/1591-951X-1113_ref7","unstructured":"Ellis IO, Carder P, Hales S, et al. Pathology reporting of breast disease in surgical excision specimens incorporating the dataset for histological reporting of breast cancer.; 2016. Available at: https:\/\/www.rcpath.org\/uploads\/assets\/7763be1c-d330-40e8-95d08f955752792a\/G148_BreastDataset-hires-Jun16.pdf."},{"key":"10.32074\/1591-951X-1113_ref8","unstructured":"Perry N, Broeders M, de Wolf C, et al. European guidelines for quality assurance in breast cancer screening and diagnosis.; 2006. Available at: papers:\/\/7fb3a579-17eb-4f3e-967a-87b6e77fe28f\/Paper\/p1630."},{"key":"10.32074\/1591-951X-1113_ref9","doi-asserted-by":"crossref","unstructured":"Bilous M. Breast core needle biopsy: issues and controversies. Mod. Pathol. 2010;23 Suppl 2:S36-45. https:\/\/doi.org\/10.1038\/modpathol.2010.34.","DOI":"10.1038\/modpathol.2010.34"},{"key":"10.32074\/1591-951X-1113_ref10","doi-asserted-by":"crossref","unstructured":"Biganzoli L, Cardoso F, Beishon M, et al. The requirements of a specialist breast centre. The Breast 2020;51:65-84. https:\/\/doi.org\/https:\/\/doi.org\/10.1016\/j.breast.2020.02.003.","DOI":"10.1016\/j.breast.2020.02.003"},{"key":"10.32074\/1591-951X-1113_ref11","unstructured":"Lee AH, Anderson N, Carder P, et al. Guidelines for non-operative diagnostic procedures and reporting in breast cancer screening. London; 2021. Available at: www.rcpath.org."},{"key":"10.32074\/1591-951X-1113_ref12","doi-asserted-by":"crossref","unstructured":"Rubio IT, Wyld L, Marotti L, et al. European guidelines for the diagnosis, treatment and follow-up of breast lesions with uncertain malignant potential (B3 lesions) developed jointly by EUSOMA, EUSOBI, ESP (BWG) and ESSO. Eur. J. Surg. Oncol. J. Eur. Soc. Surg. Oncol. Br. Assoc. Surg. Oncol. 2024;50:107292. https:\/\/doi.org\/10.1016\/j.ejso.2023.107292.","DOI":"10.1016\/j.ejso.2023.107292"},{"key":"10.32074\/1591-951X-1113_ref13","doi-asserted-by":"crossref","unstructured":"Collins LC, Connolly JL, Page DL, et al. Diagnostic agreement in the evaluation of image-guided breast core needle biopsies: results from a randomized clinical trial. Am. J. Surg. Pathol. 2004;28:126-131. https:\/\/doi.org\/10.1097\/00000478-200401000-00015.","DOI":"10.1097\/00000478-200401000-00015"},{"key":"10.32074\/1591-951X-1113_ref14","doi-asserted-by":"crossref","unstructured":"Trocchi P, Holzhausen H-J, L\u00f6ning T, et al. Intraobserver Agreement on Histopathologic Evaluations of Core Breast Biopsies. Breast J. 2017;23:215-219. https:\/\/doi.org\/10.1111\/tbj.12708.","DOI":"10.1111\/tbj.12708"},{"key":"10.32074\/1591-951X-1113_ref15","unstructured":"Lee AH, Anderson N, Carder P, et al. Guidelines for non-operative diagnostic procedures and reporting in breast cancer screening. London; 2021."},{"key":"10.32074\/1591-951X-1113_ref16","doi-asserted-by":"crossref","unstructured":"Rakha EA, Lee AHS, Jenkins JA, et al. Characterization and outcome of breast needle core biopsy diagnoses of lesions of uncertain malignant potential (B3) in abnormalities detected by mammographic screening. Int. J. Cancer 2011;129:1417-1424. https:\/\/doi.org\/10.1002\/ijc.25801.","DOI":"10.1002\/ijc.25801"},{"key":"10.32074\/1591-951X-1113_ref17","doi-asserted-by":"crossref","unstructured":"Bianchi S, Caini S, Renne G, et al. Positive predictive value for malignancy on surgical excision of breast lesions of uncertain malignant potential (B3) diagnosed by stereotactic vacuum-assisted needle core biopsy (VANCB): a large multi-institutional study in Italy. Breast 2011;20:264-270. https:\/\/doi.org\/10.1016\/j.breast.2010.12.003.","DOI":"10.1016\/j.breast.2010.12.003"},{"key":"10.32074\/1591-951X-1113_ref18","doi-asserted-by":"crossref","unstructured":"Chuba PJ, Hamre MR, Yap J, et al. Bilateral risk for subsequent breast cancer after lobular carcinoma-in-situ: analysis of surveillance, epidemiology, and end results data. J. Clin. Oncol. 2005;23:5534-5541. https:\/\/doi.org\/10.1200\/JCO.2005.04.038.","DOI":"10.1200\/JCO.2005.04.038"},{"key":"10.32074\/1591-951X-1113_ref19","unstructured":"Commission E, Consumers D-G for H and, Karsa L, et al. European guidelines for quality assurance in breast cancer screening and diagnosis - Fourth edition, supplements. (Karsa L, Holland R, Broeders M, et al., eds.). Publications Office; 2013. https:\/\/doi.org\/doi\/10.2772\/13196."},{"key":"10.32074\/1591-951X-1113_ref20","unstructured":"Perry N, Broeders M, de Wolf C, et al. European guidelines for quality assurance in breast cancer screening and diagnosis.; 2006."},{"key":"10.32074\/1591-951X-1113_ref21","doi-asserted-by":"crossref","unstructured":"Brem RF. Management of Breast Atypical Ductal Hyperplasia: Now and the Future. Radiology 2020;294:87-88. https:\/\/doi.org\/10.1148\/radiol.2019192192.","DOI":"10.1148\/radiol.2019192192"},{"key":"10.32074\/1591-951X-1113_ref22","doi-asserted-by":"crossref","unstructured":"Schiaffino S, Calabrese M, Melani EF, et al. Upgrade Rate of Percutaneously Diagnosed Pure Atypical Ductal Hyperplasia: Systematic Review and Meta-Analysis of 6458 Lesions. Radiology 2020;294:76-86. https:\/\/doi.org\/10.1148\/radiol.2019190748.","DOI":"10.1148\/radiol.2019190748"},{"key":"10.32074\/1591-951X-1113_ref23","unstructured":"WHO Classification of Tumours Editorial Board. WHO Classification of Tumours. Breast tumours. 5th ed. Lyon, France: International Agency for Research on Cancer (IARC); 2019."},{"key":"10.32074\/1591-951X-1113_ref24","doi-asserted-by":"crossref","unstructured":"Perry N, Broeders M, de Wolf C, et al. European guidelines for quality assurance in breast cancer screening and diagnosis. Fourth edition--summary document. Ann. Oncol. 2008;19:614-622. https:\/\/doi.org\/10.1093\/annonc\/mdm481.","DOI":"10.1093\/annonc\/mdm481"},{"key":"10.32074\/1591-951X-1113_ref25","doi-asserted-by":"crossref","unstructured":"von Karsa L, Arrossi S. Development and implementation of guidelines for quality assurance in breast cancer screening: the European experience. Salud Publica Mex. 2013;55:318-328. https:\/\/doi.org\/10.21149\/spm.v55i3.7215.","DOI":"10.21149\/spm.v55i3.7215"},{"key":"10.32074\/1591-951X-1113_ref26","doi-asserted-by":"crossref","unstructured":"Elfgen C, Leo C, Kubik-Huch RA, et al. Third International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions). Virchows Arch. 2023;483:5-20. https:\/\/doi.org\/10.1007\/s00428-023-03566-x.","DOI":"10.1007\/s00428-023-03566-x"},{"key":"10.32074\/1591-951X-1113_ref27","doi-asserted-by":"crossref","unstructured":"Solorzano S, Mesurolle B, Omeroglu A, et al. Flat epithelial atypia of the breast: pathological-radiological correlation. AJR. Am. J. Roentgenol. 2011;197:740-746. https:\/\/doi.org\/10.2214\/AJR.10.5265.","DOI":"10.2214\/AJR.10.5265"},{"key":"10.32074\/1591-951X-1113_ref28","doi-asserted-by":"crossref","unstructured":"Wahab RA, Lee S-J, Mulligan ME, et al. Upgrade Rate of Pure Flat Epithelial Atypia Diagnosed at Core Needle Biopsy: A Systematic Review and Meta-Analysis. Radiol. Imaging Cancer 2021;3:e200116. https:\/\/doi.org\/10.1148\/rycan.2021200116.","DOI":"10.1148\/rycan.2021200116"},{"key":"10.32074\/1591-951X-1113_ref29","doi-asserted-by":"crossref","unstructured":"Berg WA, Mrose HE, Ioffe OB. Atypical lobular hyperplasia or lobular carcinoma in situ at core-needle breast biopsy. Radiology 2001;218:503-509. https:\/\/doi.org\/10.1148\/radiology.218.2.r01fe32503.","DOI":"10.1148\/radiology.218.2.r01fe32503"},{"key":"10.32074\/1591-951X-1113_ref30","doi-asserted-by":"crossref","unstructured":"Hartmann LC, Degnim AC, Santen RJ, et al. Atypical hyperplasia of the breast--risk assessment and management options. N. Engl. J. Med. 2015;372:78-89. https:\/\/doi.org\/10.1056\/NEJMsr1407164.","DOI":"10.1056\/NEJMsr1407164"},{"key":"10.32074\/1591-951X-1113_ref31","unstructured":"Tavassoli FA, Devilee P, International Agency for Research on Cancer, et al. Pathology and genetics of tumours of the breast and female genital organs. In: World Health Organisation Classification of Tumours. Lyon, France: International Agency for Research on Cancer; 2003:432."},{"key":"10.32074\/1591-951X-1113_ref32","doi-asserted-by":"crossref","unstructured":"Tavassoli FA. Lobular neoplasia: evolution of its significance and morphologic spectrum. Int. J. Surg. Pathol. 2010;18:174S-177S. https:\/\/doi.org\/10.1177\/1066896910370879.","DOI":"10.1177\/1066896910370879"},{"key":"10.32074\/1591-951X-1113_ref33","doi-asserted-by":"crossref","unstructured":"Calhoun BC, Collins LC. Recommendations for excision following core needle biopsy of the breast: a contemporary evaluation of the literature. Histopathology 2016;68:138-151. https:\/\/doi.org\/10.1111\/his.12852.","DOI":"10.1111\/his.12852"},{"key":"10.32074\/1591-951X-1113_ref34","doi-asserted-by":"crossref","unstructured":"Szynglarewicz B, Kasprzak P, Ha\u0142o\u0144 A, et al. Lobular carcinoma in situ of the breast - correlation between minimally invasive biopsy and final pathology. Arch. Med. Sci. 2017;13:617-623. https:\/\/doi.org\/10.5114\/aoms.2016.61815.","DOI":"10.5114\/aoms.2016.61815"},{"key":"10.32074\/1591-951X-1113_ref35","doi-asserted-by":"crossref","unstructured":"Muller KE, Roberts E, Zhao L, et al. Isolated Atypical Lobular Hyperplasia Diagnosed on Breast Biopsy: Low Upgrade Rate on Subsequent Excision With Long-Term Follow-up. Arch. Pathol. Lab. Med. 2018;142:391-395. https:\/\/doi.org\/10.5858\/arpa.2017-0155-OA.","DOI":"10.5858\/arpa.2017-0155-OA"},{"key":"10.32074\/1591-951X-1113_ref36","doi-asserted-by":"crossref","unstructured":"Susnik B, Day D, Abeln E, et al. Surgical Outcomes of Lobular Neoplasia Diagnosed in Core Biopsy: Prospective Study of 316 Cases. Clin. Breast Cancer 2016;16:507-513. https:\/\/doi.org\/10.1016\/j.clbc.2016.06.003.","DOI":"10.1016\/j.clbc.2016.06.003"},{"key":"10.32074\/1591-951X-1113_ref37","doi-asserted-by":"crossref","unstructured":"Sullivan ME, Khan SA, Sullu Y, et al. Lobular carcinoma in situ variants in breast cores: potential for misdiagnosis, upgrade rates at surgical excision, and practical implications. Arch. Pathol. Lab. Med. 2010;134:1024-1028. https:\/\/doi.org\/10.5858\/2009-0300-OA.1.","DOI":"10.5858\/2009-0300-OA.1"},{"key":"10.32074\/1591-951X-1113_ref38","doi-asserted-by":"crossref","unstructured":"Flanagan MR, Rendi MH, Calhoun KE, et al. Pleomorphic Lobular Carcinoma In Situ: Radiologic-Pathologic Features and Clinical Management. Ann. Surg. Oncol. 2015;22:4263-4269. https:\/\/doi.org\/10.1245\/s10434-015-4552-x.","DOI":"10.1245\/s10434-015-4552-x"},{"key":"10.32074\/1591-951X-1113_ref39","doi-asserted-by":"crossref","unstructured":"Fasola CE, Chen JJ, Jensen KC, et al. Characteristics and clinical outcomes of pleomorphic lobular carcinoma in situ of the breast. Breast J. 2018;24:66-69. https:\/\/doi.org\/10.1111\/tbj.12843.","DOI":"10.1111\/tbj.12843"},{"key":"10.32074\/1591-951X-1113_ref40","doi-asserted-by":"crossref","unstructured":"Plaza MJ, Swintelski C, Yaziji H, et al. Phyllodes tumor: review of key imaging characteristics. Breast Dis. 2015;35:79-86. https:\/\/doi.org\/10.3233\/BD-150399.","DOI":"10.3233\/BD-150399"},{"key":"10.32074\/1591-951X-1113_ref41","doi-asserted-by":"crossref","unstructured":"Lerwill MF, Lee AHS, Tan PH. Fibroepithelial tumours of the breast-a review. Virchows Arch. 2022;480:45-63. https:\/\/doi.org\/10.1007\/s00428-021-03175-6.","DOI":"10.1007\/s00428-021-03175-6"},{"key":"10.32074\/1591-951X-1113_ref42","doi-asserted-by":"crossref","unstructured":"Eiada R, Chong J, Kulkarni S, et al. Papillary lesions of the breast: MRI, ultrasound, and mammographic appearances. AJR. Am. J. Roentgenol. 2012;198:264-271. https:\/\/doi.org\/10.2214\/AJR.11.7922.","DOI":"10.2214\/AJR.11.7922"},{"key":"10.32074\/1591-951X-1113_ref43","doi-asserted-by":"crossref","unstructured":"Cohen MA, Newell MS. Radial Scars of the Breast Encountered at Core Biopsy: Review of Histologic, Imaging, and Management Considerations. AJR. Am. J. Roentgenol. 2017;209:1168-1177. https:\/\/doi.org\/10.2214\/AJR.17.18156.","DOI":"10.2214\/AJR.17.18156"},{"key":"10.32074\/1591-951X-1113_ref44","doi-asserted-by":"crossref","unstructured":"Dang BQ, Miles B, Young P, et al. Mucocele-Like Lesion of the Breast. Cureus 2023;15:e37829. https:\/\/doi.org\/10.7759\/cureus.37829.","DOI":"10.7759\/cureus.37829"},{"key":"10.32074\/1591-951X-1113_ref45","doi-asserted-by":"crossref","unstructured":"Rakha EA, Shaaban AM, Haider SA, et al. Outcome of pure mucocele-like lesions diagnosed on breast core biopsy. Histopathology 2013;62:894-898. https:\/\/doi.org\/10.1111\/his.12081.","DOI":"10.1111\/his.12081"},{"key":"10.32074\/1591-951X-1113_ref46","doi-asserted-by":"crossref","unstructured":"Gibreel WO, Boughey JC. Mucocele-Like Lesions of the Breast: Rate of Upstaging and Cancer Development. Ann. Surg. Oncol. 2016;23:3838-3842. https:\/\/doi.org\/10.1245\/s10434-016-5352-7.","DOI":"10.1245\/s10434-016-5352-7"},{"key":"10.32074\/1591-951X-1113_ref47","doi-asserted-by":"crossref","unstructured":"Meares AL, Frank RD, Degnim AC, et al. Mucocele-like lesions of the breast: a clinical outcome and histologic analysis of 102 cases. Hum. Pathol. 2016;49:33-38. https:\/\/doi.org\/10.1016\/j.humpath.2015.10.004.","DOI":"10.1016\/j.humpath.2015.10.004"},{"key":"10.32074\/1591-951X-1113_ref48","doi-asserted-by":"crossref","unstructured":"Bucchi L, Belli P, Benelli E, et al. Recommendations for breast imaging follow-up of women with a previous history of breast cancer: position paper from the Italian Group for Mammography Screening (GISMa) and the Italian College of Breast Radiologists (ICBR) by SIRM. Radiol. Med. 2016;121:891-896. https:\/\/doi.org\/10.1007\/s11547-016-0676-8.","DOI":"10.1007\/s11547-016-0676-8"},{"key":"10.32074\/1591-951X-1113_ref49","doi-asserted-by":"crossref","unstructured":"Strachan C, Horgan K, Millican-Slater RA, et al. Outcome of a new patient pathway for managing B3 breast lesions by vacuum-assisted biopsy: time to change current UK practice? J. Clin. Pathol. 2016;69:248-254. https:\/\/doi.org\/10.1136\/jclinpath-2015-203018.","DOI":"10.1136\/jclinpath-2015-203018"},{"key":"10.32074\/1591-951X-1113_ref50","unstructured":"Senonetwork. Raccomandazioni Senonetwork Di Buona Pratica Clinica - Lesioni B3.; 2020. Available at: https:\/\/www.senonetwork.it\/it\/raccomandazioni\/1-3798-1-#."},{"key":"10.32074\/1591-951X-1113_ref51","doi-asserted-by":"crossref","unstructured":"Wong SM, King T, Boileau J-F, et al. Population-Based Analysis of Breast Cancer Incidence and Survival Outcomes in Women Diagnosed with Lobular Carcinoma In Situ. Ann. Surg. Oncol. 2017;24:2509-2517. https:\/\/doi.org\/10.1245\/s10434-017-5867-6.","DOI":"10.1245\/s10434-017-5867-6"},{"key":"10.32074\/1591-951X-1113_ref52","doi-asserted-by":"crossref","unstructured":"Lee CH, Carter D, Philpotts LE, et al. Ductal carcinoma in situ diagnosed with stereotactic core needle biopsy: can invasion be predicted? Radiology 2000;217:466-470. https:\/\/doi.org\/10.1148\/radiology.217.2.r00nv08466.","DOI":"10.1148\/radiology.217.2.r00nv08466"},{"key":"10.32074\/1591-951X-1113_ref53","doi-asserted-by":"crossref","unstructured":"Ellis IO, Coleman D, Wells C, et al. Impact of a national external quality assessment scheme for breast pathology in the UK. J. Clin. Pathol. 2006;59:138-145. https:\/\/doi.org\/10.1136\/jcp.2004.025551.","DOI":"10.1136\/jcp.2004.025551"},{"key":"10.32074\/1591-951X-1113_ref54","doi-asserted-by":"crossref","unstructured":"El Sharouni M-A, Postma EL, Menezes GLG, et al. High Prevalence of MRI-Detected Contralateral and Ipsilateral Malignant Findings in Patients With Invasive Ductolobular Breast Cancer: Impact on Surgical Management. Clin. Breast Cancer 2016;16:269-275. https:\/\/doi.org\/10.1016\/j.clbc.2015.10.002.","DOI":"10.1016\/j.clbc.2015.10.002"},{"key":"10.32074\/1591-951X-1113_ref55","doi-asserted-by":"crossref","unstructured":"Harris GC, Denley HE, Pinder SE, et al. Correlation of histologic prognostic factors in core biopsies and therapeutic excisions of invasive breast carcinoma. Am. J. Surg. Pathol. 2003;27:11-15. https:\/\/doi.org\/10.1097\/00000478-200301000-00002.","DOI":"10.1097\/00000478-200301000-00002"},{"key":"10.32074\/1591-951X-1113_ref56","doi-asserted-by":"crossref","unstructured":"Rakha EA, Ellis IO. An overview of assessment of prognostic and predictive factors in breast cancer needle core biopsy specimens. J. Clin. Pathol. 2007;60:1300-1306. https:\/\/doi.org\/10.1136\/jcp.2006.045377.","DOI":"10.1136\/jcp.2006.045377"},{"key":"10.32074\/1591-951X-1113_ref57","doi-asserted-by":"crossref","unstructured":"Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991;19:403-410. https:\/\/doi.org\/10.1111\/j.1365-2559.1991.tb00229.x.","DOI":"10.1111\/j.1365-2559.1991.tb00229.x"},{"key":"10.32074\/1591-951X-1113_ref58","doi-asserted-by":"crossref","unstructured":"Salgado R, Denkert C, Demaria S, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann. Oncol. 2015;26:259-271. https:\/\/doi.org\/10.1093\/annonc\/mdu450.","DOI":"10.1093\/annonc\/mdu450"},{"key":"10.32074\/1591-951X-1113_ref59","doi-asserted-by":"crossref","unstructured":"Burstein HJ, Curigliano G, Loibl S, et al. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Ann. Oncol. 2019;30:1541-1557. https:\/\/doi.org\/10.1093\/annonc\/mdz235.","DOI":"10.1093\/annonc\/mdz235"},{"key":"10.32074\/1591-951X-1113_ref60","doi-asserted-by":"crossref","unstructured":"Khoury T, Peng X, Yan L, et al. Tumor-Infiltrating Lymphocytes in Breast Cancer: Evaluating Interobserver Variability, Heterogeneity, and Fidelity of Scoring Core Biopsies. Am. J. Clin. Pathol. 2018;150:441-450. https:\/\/doi.org\/10.1093\/ajcp\/aqy069.","DOI":"10.1093\/ajcp\/aqy069"},{"key":"10.32074\/1591-951X-1113_ref61","doi-asserted-by":"crossref","unstructured":"Loibl S, Andr\u00e9 F, Bachelot T, et al. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 2024;35:159-182. https:\/\/doi.org\/10.1016\/j.annonc.2023.11.016.","DOI":"10.1016\/j.annonc.2023.11.016"},{"key":"10.32074\/1591-951X-1113_ref62","doi-asserted-by":"crossref","unstructured":"Allison KH, Hammond MEH, Dowsett M, et al. Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO\/CAP Guideline Update. J. Clin. Oncol. 2020;38:1346-1366. https:\/\/doi.org\/10.1200\/JCO.19.02309.","DOI":"10.1200\/JCO.19.02309"},{"key":"10.32074\/1591-951X-1113_ref63","doi-asserted-by":"crossref","unstructured":"Wolff AC, Hammond MEH, Allison KH, et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update. J. Clin. Oncol. 2018;36:2105-2122. https:\/\/doi.org\/10.1200\/JCO.2018.77.8738.","DOI":"10.1200\/JCO.2018.77.8738"},{"key":"10.32074\/1591-951X-1113_ref64","doi-asserted-by":"crossref","unstructured":"Wolff AC, Somerfield MR, Dowsett M, et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-College of American Pathologists Guideline Update. J. Clin. Oncol. 2023;41:3867-3872. https:\/\/doi.org\/10.1200\/JCO.22.02864.","DOI":"10.1200\/JCO.22.02864"},{"key":"10.32074\/1591-951X-1113_ref65","doi-asserted-by":"crossref","unstructured":"Duffy MJ, Harbeck N, Nap M, et al. Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM). Eur. J. Cancer 2017;75:284-298. https:\/\/doi.org\/10.1016\/j.ejca.2017.01.017.","DOI":"10.1016\/j.ejca.2017.01.017"},{"key":"10.32074\/1591-951X-1113_ref66","doi-asserted-by":"crossref","unstructured":"Nielsen TO, Leung SCY, Rimm DL, et al. Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group. J. Natl. Cancer Inst. 2021;113:808-819. https:\/\/doi.org\/10.1093\/jnci\/djaa201.","DOI":"10.1093\/jnci\/djaa201"},{"key":"10.32074\/1591-951X-1113_ref67","doi-asserted-by":"crossref","unstructured":"Leung SCY, Nielsen TO, Zabaglo L, et al. Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration. NPJ Breast Cancer 2016;2:16014. https:\/\/doi.org\/10.1038\/npjbcancer.2016.14.","DOI":"10.1038\/npjbcancer.2016.14"},{"key":"10.32074\/1591-951X-1113_ref68","doi-asserted-by":"crossref","unstructured":"Ahn S, Lee J, Cho M-S, et al. Evaluation of Ki-67 Index in Core Needle Biopsies and Matched Breast Cancer Surgical Specimens. Arch. Pathol. Lab. Med. 2018;142:364-368. https:\/\/doi.org\/10.5858\/arpa.2017-0014-OA.","DOI":"10.5858\/arpa.2017-0014-OA"},{"key":"10.32074\/1591-951X-1113_ref69","doi-asserted-by":"crossref","unstructured":"Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020. Ann. Oncol. 2019;30:1194-1220. https:\/\/doi.org\/10.1093\/annonc\/mdz173.","DOI":"10.1093\/annonc\/mdz173"},{"key":"10.32074\/1591-951X-1113_ref70","doi-asserted-by":"crossref","unstructured":"Scatena C, Lemmi E, Cremonini A, et al. Heterogeneity of ER, PgR, HER2 and Ki67 in multifocal\/multicentric breast cancer with a single histotype and same grade: implications for pathologists and oncologists from a large multi-institutional series. In: 14th European Breast Cancer Conference. Milan; 2024. https:\/\/doi.org\/10.1016\/j.ejca.2024.113619.","DOI":"10.1016\/j.ejca.2024.113619"},{"key":"10.32074\/1591-951X-1113_ref71","doi-asserted-by":"crossref","unstructured":"Santinelli A, Pisa E, Stramazzotti D, et al. HER-2 status discrepancy between primary breast cancer and metastatic sites. Impact on target therapy. Int. J. Cancer 2008;122:999-1004. https:\/\/doi.org\/10.1002\/ijc.23051.","DOI":"10.1002\/ijc.23051"},{"key":"10.32074\/1591-951X-1113_ref72","doi-asserted-by":"crossref","unstructured":"Kinoe H, Yamanouchi K, Kuba S, et al. Discordance of hormone receptor, human epidermal growth factor receptor-2, and Ki-67 between primary breast cancer and synchronous axillary lymph node metastasis. J. BUON. 2018;23:60-66.\nhttps:\/\/doi.org\/10.1016\/j.jamcollsurg.2018.08.012","DOI":"10.1016\/j.jamcollsurg.2018.08.012"},{"key":"10.32074\/1591-951X-1113_ref73","unstructured":"Zhao S, Xu L, Liu W, et al. Comparison of the expression of prognostic biomarkers between primary tumor and axillary lymph node metastases in breast cancer. Int. J. Clin. Exp. Pathol. 2015;8:5744-5748."},{"key":"10.32074\/1591-951X-1113_ref74","doi-asserted-by":"crossref","unstructured":"Xi X, Huang X-W, Yuan H-Z, et al. Biomarker heterogeneity between primary breast cancer and synchronous axillary lymph node metastases. Oncol. Lett. 2020;20:273. https:\/\/doi.org\/10.3892\/ol.2020.12136.","DOI":"10.3892\/ol.2020.12136"},{"key":"10.32074\/1591-951X-1113_ref75","doi-asserted-by":"crossref","unstructured":"Marletta S, Giorlandino A, Cavallo E, et al. Discordance of Biomarker Expression Profile between Primary Breast Cancer and Synchronous Axillary Lymph Node Metastasis in Preoperative Core Needle Biopsy. Diagnostics (Basel, Switzerland) 2024;14. https:\/\/doi.org\/10.3390\/diagnostics14030259.","DOI":"10.3390\/diagnostics14030259"},{"key":"10.32074\/1591-951X-1113_ref76","doi-asserted-by":"crossref","unstructured":"Balasubramanian I, Fleming CA, Corrigan MA, et al. Meta-analysis of the diagnostic accuracy of ultrasound-guided fine-needle aspiration and core needle biopsy in diagnosing axillary lymph node metastasis. Br. J. Surg. 2018;105:1244-1253. https:\/\/doi.org\/10.1002\/bjs.10920.","DOI":"10.1002\/bjs.10920"},{"key":"10.32074\/1591-951X-1113_ref77","doi-asserted-by":"crossref","unstructured":"Xu Q, Wang J, Wang J, et al. The effectiveness of ultrasound-guided core needle biopsy in detecting lymph node metastases in the axilla in patients with breast cancer: systematic review and meta-analysis. Clinics (Sao Paulo). 2023;78:100207. https:\/\/doi.org\/10.1016\/j.clinsp.2023.100207.","DOI":"10.1016\/j.clinsp.2023.100207"},{"key":"10.32074\/1591-951X-1113_ref78","doi-asserted-by":"crossref","unstructured":"Tolaney SM, Barry WT, Dang CT, et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N. Engl. J. Med. 2015;372:134-141. https:\/\/doi.org\/10.1056\/NEJMoa1406281.","DOI":"10.1056\/NEJMoa1406281"},{"key":"10.32074\/1591-951X-1113_ref79","doi-asserted-by":"crossref","unstructured":"Caudle AS, Yang WT, Krishnamurthy S, et al. Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection. J. Clin. Oncol. 2016;34:1072-1078. https:\/\/doi.org\/10.1200\/JCO.2015.64.0094.","DOI":"10.1200\/JCO.2015.64.0094"},{"key":"10.32074\/1591-951X-1113_ref80","doi-asserted-by":"crossref","unstructured":"Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet. Oncol. 2013;14:609-618. https:\/\/doi.org\/10.1016\/S1470-2045(13)70166-9.","DOI":"10.1016\/S1470-2045(13)70166-9"},{"key":"10.32074\/1591-951X-1113_ref81","doi-asserted-by":"crossref","unstructured":"Kuemmel S, Heil J, Rueland A, et al. A Prospective, Multicenter Registry Study to Evaluate the Clinical Feasibility of Targeted Axillary Dissection (TAD) in Node-positive Breast Cancer Patients. Ann. Surg. 2022;276:e553-e562. https:\/\/doi.org\/10.1097\/SLA.0000000000004572.","DOI":"10.1097\/SLA.0000000000004572"},{"key":"10.32074\/1591-951X-1113_ref82","doi-asserted-by":"crossref","unstructured":"Costarelli L, Arienzo F, Broglia L, et al. Clipping a Positive Lymph Node Improves Accuracy of Nodal Staging After Neoadjuvant Chemotherapy for Breast Cancer Patients, but Does It Drive Management Changes? Ann. Surg. Oncol. 2024;31:3186-3193. https:\/\/doi.org\/10.1245\/s10434-024-15052-y.","DOI":"10.1245\/s10434-024-15052-y"},{"key":"10.32074\/1591-951X-1113_ref83","doi-asserted-by":"crossref","unstructured":"Wiener AA, Hanlon BM, Schumacher JR, et al. Reexamining Time From Breast Cancer Diagnosis to Primary Breast Surgery. JAMA Surg. 2023;158:485-492. https:\/\/doi.org\/10.1001\/jamasurg.2022.8388.","DOI":"10.1001\/jamasurg.2022.8388"}],"container-title":["Pathologica"],"original-title":[],"link":[{"URL":"https:\/\/www.pathologica.it\/article\/view\/1478","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T12:54:27Z","timestamp":1751979267000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.pathologica.it\/article\/view\/1478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":83,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,6]]}},"URL":"https:\/\/doi.org\/10.32074\/1591-951x-1113","relation":{},"ISSN":["1591-951X"],"issn-type":[{"value":"1591-951X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]}}}